131 related articles for article (PubMed ID: 38839372)
1. Understanding the Manufacturing Process of Lipid Nanoparticles for mRNA Delivery Using Machine Learning.
Sato S; Sano S; Muto H; Kubara K; Kondo K; Miyazaki T; Suzuki Y; Uemoto Y; Ukai K
Chem Pharm Bull (Tokyo); 2024; 72(6):529-539. PubMed ID: 38839372
[TBL] [Abstract][Full Text] [Related]
2. 3D-printed microfluidic device for high-throughput production of lipid nanoparticles incorporating SARS-CoV-2 spike protein mRNA.
Lin WS; Bostic WKV; Malmstadt N
Lab Chip; 2024 Jan; 24(2):162-170. PubMed ID: 38165143
[TBL] [Abstract][Full Text] [Related]
3. Microfluidic production of mRNA-loaded lipid nanoparticles for vaccine applications.
Lopes C; Cristóvão J; Silvério V; Lino PR; Fonte P
Expert Opin Drug Deliv; 2022 Oct; 19(10):1381-1395. PubMed ID: 36223174
[TBL] [Abstract][Full Text] [Related]
4. Development of a Microfluidic-Based Post-Treatment Process for Size-Controlled Lipid Nanoparticles and Application to siRNA Delivery.
Kimura N; Maeki M; Sato Y; Ishida A; Tani H; Harashima H; Tokeshi M
ACS Appl Mater Interfaces; 2020 Jul; 12(30):34011-34020. PubMed ID: 32667806
[TBL] [Abstract][Full Text] [Related]
5. On the size-regulation of RNA-loaded lipid nanoparticles synthesized by microfluidic device.
Okuda K; Sato Y; Iwakawa K; Sasaki K; Okabe N; Maeki M; Tokeshi M; Harashima H
J Control Release; 2022 Aug; 348():648-659. PubMed ID: 35716883
[TBL] [Abstract][Full Text] [Related]
6. Long-term stability and immunogenicity of lipid nanoparticle COVID-19 mRNA vaccine is affected by particle size.
Shi R; Liu X; Wang Y; Pan M; Wang S; Shi L; Ni B
Hum Vaccin Immunother; 2024 Dec; 20(1):2342592. PubMed ID: 38714327
[TBL] [Abstract][Full Text] [Related]
7. Importance of Process Parameters Influencing the Mean Diameters of siRNA-Containing Lipid Nanoparticles (LNPs) on the in Vitro Activity of Prepared LNPs.
Nakamura K; Aihara K; Ishida T
Biol Pharm Bull; 2022; 45(4):497-507. PubMed ID: 35370275
[TBL] [Abstract][Full Text] [Related]
8. Understanding the formation mechanism of lipid nanoparticles in microfluidic devices with chaotic micromixers.
Maeki M; Fujishima Y; Sato Y; Yasui T; Kaji N; Ishida A; Tani H; Baba Y; Harashima H; Tokeshi M
PLoS One; 2017; 12(11):e0187962. PubMed ID: 29182626
[TBL] [Abstract][Full Text] [Related]
9. Chemistry of Lipid Nanoparticles for RNA Delivery.
Eygeris Y; Gupta M; Kim J; Sahay G
Acc Chem Res; 2022 Jan; 55(1):2-12. PubMed ID: 34850635
[TBL] [Abstract][Full Text] [Related]
10. Throughput-scalable manufacturing of SARS-CoV-2 mRNA lipid nanoparticle vaccines.
Shepherd SJ; Han X; Mukalel AJ; El-Mayta R; Thatte AS; Wu J; Padilla MS; Alameh MG; Srikumar N; Lee D; Weissman D; Issadore D; Mitchell MJ
Proc Natl Acad Sci U S A; 2023 Aug; 120(33):e2303567120. PubMed ID: 37556502
[TBL] [Abstract][Full Text] [Related]
11. Taylor Dispersion Analysis to support lipid-nanoparticle formulations for mRNA vaccines.
Malburet C; Leclercq L; Cotte JF; Thiebaud J; Bazin E; Garinot M; Cottet H
Gene Ther; 2023 May; 30(5):421-428. PubMed ID: 36316446
[TBL] [Abstract][Full Text] [Related]
12. Ready-to-Use-Type Lyophilized Lipid Nanoparticle Formulation for the Postencapsulation of Messenger RNA.
Tanaka H; Hagiwara S; Shirane D; Yamakawa T; Sato Y; Matsumoto C; Ishizaki K; Hishinuma M; Chida K; Sasaki K; Yonemochi E; Ueda K; Higashi K; Moribe K; Tadokoro T; Maenaka K; Taneichi S; Nakai Y; Tange K; Sakurai Y; Akita H
ACS Nano; 2023 Feb; 17(3):2588-2601. PubMed ID: 36719091
[TBL] [Abstract][Full Text] [Related]
13. Process Robustness in Lipid Nanoparticle Production: A Comparison of Microfluidic and Turbulent Jet Mixing.
O'Brien Laramy MN; Costa AP; Cebrero YM; Joseph J; Sarode A; Zang N; Kim LJ; Hofmann K; Wang S; Goyon A; Koenig SG; Hammel M; Hura GL
Mol Pharm; 2023 Aug; 20(8):4285-4296. PubMed ID: 37462906
[TBL] [Abstract][Full Text] [Related]
14. Mesoscopic Structure of Lipid Nanoparticle Formulations for mRNA Drug Delivery: Comirnaty and Drug-Free Dispersions.
Unruh T; Götz K; Vogel C; Fröhlich E; Scheurer A; Porcar L; Steiniger F
ACS Nano; 2024 Apr; 18(13):9746-9764. PubMed ID: 38514237
[TBL] [Abstract][Full Text] [Related]
15. Developing Biodegradable Lipid Nanoparticles for Intracellular mRNA Delivery and Genome Editing.
Qiu M; Li Y; Bloomer H; Xu Q
Acc Chem Res; 2021 Nov; 54(21):4001-4011. PubMed ID: 34668716
[TBL] [Abstract][Full Text] [Related]
16. Optimization of formulation and atomization of lipid nanoparticles for the inhalation of mRNA.
Miao H; Huang K; Li Y; Li R; Zhou X; Shi J; Tong Z; Sun Z; Yu A
Int J Pharm; 2023 Jun; 640():123050. PubMed ID: 37201764
[TBL] [Abstract][Full Text] [Related]
17. Formulating and Characterizing Lipid Nanoparticles for Gene Delivery using a Microfluidic Mixing Platform.
Bailey-Hytholt CM; Ghosh P; Dugas J; Zarraga IE; Bandekar A
J Vis Exp; 2021 Feb; (168):. PubMed ID: 33720139
[TBL] [Abstract][Full Text] [Related]
18. Hydrophobic scaffolds of pH-sensitive cationic lipids contribute to miscibility with phospholipids and improve the efficiency of delivering short interfering RNA by small-sized lipid nanoparticles.
Sato Y; Okabe N; Note Y; Hashiba K; Maeki M; Tokeshi M; Harashima H
Acta Biomater; 2020 Jan; 102():341-350. PubMed ID: 31733331
[TBL] [Abstract][Full Text] [Related]
19. Mechanistic Studies of an Automated Lipid Nanoparticle Reveal Critical Pharmaceutical Properties Associated with Enhanced mRNA Functional Delivery In Vitro and In Vivo.
Cui L; Hunter MR; Sonzini S; Pereira S; Romanelli SM; Liu K; Li W; Liang L; Yang B; Mahmoudi N; Desai AS
Small; 2022 Mar; 18(9):e2105832. PubMed ID: 34914866
[TBL] [Abstract][Full Text] [Related]
20. A Basic Method for Formulating mRNA-Lipid Nanoparticle Vaccines in the Lab.
Jarzebska NT; Frei J; Mellett M; Kündig TM; Pascolo S; Reichmuth AM
Methods Mol Biol; 2024; 2786():237-254. PubMed ID: 38814398
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
